http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109568315-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c98e71d9dccf555d622fb2fc27b6ab9c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c478f5f62649cd5c57698d0b566c2681 |
| publicationDate | 2019-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109568315-A |
| titleOfInvention | Application of carbonic anhydrase inhibitors in the preparation of anti-atherosclerotic drugs |
| abstract | The invention belongs to the field of anti-arteriosclerosis drugs, in particular to the application of carbonic anhydrase inhibitors in the preparation of anti-atherosclerosis drugs. This study is the first to find that CA1 is highly expressed in atherosclerotic calcified tissue, and CA1 is associated with vascular smooth muscle calcification and affects cell proliferation and apoptosis. Methazolamide, an inhibitor of CA1, can significantly attenuate the process of atherosclerosis and exert an inhibitory effect on atherosclerotic inflammatory factors. The above results suggest that calcification plays an important role in atherosclerosis, and that CA1-dominated calcification promotes the atherosclerotic course. Methazolamide has a potential therapeutic effect on atherosclerosis by inhibiting CA1 expression. These findings not only further illustrate the close relationship between atherosclerosis and calcification, but also explore the calcification mechanism of the disease, and also prove that inhibiting calcification is a key point in the treatment of atherosclerosis. This study provides new ideas for the treatment of this disease. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114533849-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115671100-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113116889-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112190590-A |
| priorityDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 552.